Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

@article{Pospisilik2003DipeptidylPI,
  title={Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.},
  author={John Andrew Pospisilik and Jennifer Martin and Timothy Doty and Jan Adam Ehses and Nathalie Pamir and Francis C Lynn and Shalea Piteau and Hans-Ulrich Demuth and Christopher H. S. McIntosh and Raymond A. Pederson},
  journal={Diabetes},
  year={2003},
  volume={52 3},
  pages={741-50}
}
Recent studies into the physiology of the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have added stimulation of beta-cell growth, differentiation, and cell survival to well-documented, potent insulinotropic effects. Unfortunately, the therapeutic potential of these hormones is limited by their rapid enzymatic inactivation in vivo by dipeptidyl peptidase IV (DP IV). Inhibition of DP IV, so as to enhance circulating incretin levels, has proved… CONTINUE READING